HDinHD: Open Source Science for the HD Research Community
The goal of HDinHD is to foster and support a collaborative community united in its drive to accelerate the development of therapeutics that will delay the onset and/or ameliorate the effects of Huntington’s disease. HDinHD seeks to achieve this through:
- Sharing HD-related primary scientific data
- Sharing analyses and computational models built from HD-related scientific data
- Providing browsing and data interrogation tools over both primary and analyzed data that facilitate data exploration and hypothesis generation
- Building a forum for HD researchers to highlight their data, tools, know-how and insight to the community
The HDinHD website is currently a joint development effort by CHDI and UCLA, through the laboratory of Dr. Giovanni Coppola. As you will see when you Register for access, HDinHD highlights data and tools provided by the broader community. If you are interested in Contributing Data to HDinHD, suggest links to other HD-related scientific data or websites, or would otherwise like to provide Feedback to us, we encourage you to do so. HDinHD is for the community; please help us tailor and grow HDinHD in a direction that can make a difference to your research, and ultimately, to improve the lives of HD families.
Want to learn more about HDinHD?
| Watch a detailed video overview of HDinHD presented at the 16th Annual HD Therapeutics Conference (April 2021). The video outlines data resources and tools within HDinHD and provides a detailed demonstration of the new HD Explorer tool. |
Read the following publication introducing HDinHD: HDinHD: A Rich Data Portal for Huntington’s Disease Research, J Huntingtons Dis., 10, 405-412
Latest news and publications from around the HD Ecosystem
HDBuzz
- Could rewiring the brain’s “brakes” improve movement in Huntington’s disease?
- Your Voice Matters: Using Speech to Monitor Huntington’s Disease
- Can’t Get You Out of My Head: The Huntington’s Disease Symptom That’s More Than Just Repetition
- AMT-130 at Four Years: Hopeful Signs, Complex Controls
- September 2026: This month in Huntington’s disease research
Literature
- Huntington's disease vasculopathy is barrier-type-selective and arteriolar-dominant with spatially-coupled astrogliosis and reversible by S1pr1 stimulation
- Extracellular Vesicles and Exosomes as Biomarkers in Huntington's Disease: Uncovering Pathogenic Insights and Pioneering Therapies
- Chaperone-mediated remodelling of mutant huntingtin
- Sex-dependent mild cardiac dysfunction and neurometabolic abnormalities in a model of Huntington's disease
- Zebrafish as an Alternative Animal Model of Huntington's Disease: Challenges and Future Directions
New
- FDA Approves Hovilpri for Refractory HSV Lesions - Specialty Pharmacy Continuum
- Arexera Therapeutics, Formerly Atalanta Therapeutics, Unveils New Corporate Identity and ...
- uniQure assumed with a Buy at UBS - TipRanks.com
- Gene and Cell Therapies Targeting CNS Disorders Market - openPR.com
- Jennifer Lynne Barretta Obituary (2026) - Elkhart, IN - Stemm Lawson Peterson Funeral ...




